CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved ou
CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, multicenter phase III trialreported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
https://meetinglibrary.asco.org/record/160063/abstract
Although fewer tumors could be resected in patients treated with preoperative therapy compared with those on standard care (down from 72 to 62 per cent) there was a markedly increased rate of complete resections, said study author Geertjan Van Tienhoven MD, PhD, a radiation oncologist at the Academic Medical Center in Amsterdam, Netherlands, who is a member of the Dutch Pancreatic Cancer Group. He discusses the PREOPANC-1 study implications with the Audio Journal of Oncology.
Tags
Related Episodes
Vantictumab Combination Benefits Patients with Stage IV Pancreatic Cancer
Audio Journal of Oncology COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in wh
ASCO Audio Journal of Oncology – August 1st 2006
John Neoptolemos Wilko Weichert Christophe Nemos Pancreatic Cancer: Adjuvant Chemotherapy Improves Outlook for Patients with Resectable Tumors – ESPAC Trial Results REFERENCE: National Cancer Re
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA